paclitaxel sold brand name taxol among others chemotherapy medication used treat ovarian cancer esophageal cancer breast cancer lung cancer kaposis sarcoma cervical cancer pancreatic administered intravenous also albuminbound common side effects include hair loss bone marrow suppression numbness allergic reactions muscle pains side effects include heart problems increased risk infection lung concerns use pregnancy may cause birth paclitaxel taxane family works interference normal function microtubules cell paclitaxel isolated pacific yew approved medical use world health organizations list essential made precursors recently cell paclitaxel approved uk ovarian breast lung bladder prostate melanoma esophageal types solid tumor cancers well kaposis recommended national institute health care excellence nice guidance june nonsmallcell lung cancer patients unsuitable curative treatment firstline secondline treatment ovarian cancer september nice recommended paclitaxel treatment advanced breast cancer failure anthracyclic chemotherapy firstline use limited clinical trials september nice recommended paclitaxel used adjuvant treatment early nodepositive breast approved united states treatment breast pancreatic ovarian kaposis sarcoma nonsmallcell lung albuminbound paclitaxel brand name abraxane also called nabpaclitaxel alternative formulation paclitaxel bound albumin nanoparticles much clinical toxicity paclitaxel associated solvent cremophor el dissolved abraxis bioscience developed abraxane paclitaxel bonded albumin alternative delivery agent often toxic solvent delivery method approved fda january treatment breast cancer failure combination chemotherapy metastatic disease relapse within six months adjuvant since approved locally advanced metastatic nonsmall cell lung cancer metastatic adenocarcinoma pancreas synthetic approaches paclitaxel production led development docetaxel docetaxel similar set clinical uses paclitaxel marketed brand name taxotere taxanes including paclitaxel iii baccatin iii paclitaxel c found leaves shells finding compounds shells considered discarded material massproduced many food industries interest future availability paclitaxel used antiproliferative agent prevention restenosis recurrent narrowing coronary peripheral stents locally delivered wall artery paclitaxel coating limits growth neointima scar tissue within paclitaxel drugeluting stents coronary artery placement sold trade name taxus boston scientific united states paclitaxel drugeluting stents femoropopliteal artery placement also available common side effects include nausea vomiting loss appetite change taste thinned brittle hair pain joints arms legs lasting two three days changes color nails tingling hands serious side effects unusual bruising bleeding pain redness swelling injection site handfoot syndrome change normal bowel habits two days fever chills cough sore throat difficulty swallowing dizziness shortness breath severe exhaustion skin rash facial flushing female infertility ovarian damage chest pain also neuropathy may also dexamethasone given prior paclitaxel infusion mitigate side number side effects associated excipient used cremophor el polyoxyethylated castor oil allergies cyclosporine teniposide drugs delivered polyoxyethylated castor oil may increase risk adverse reactions paclitaxel one several cytoskeletal drugs target tubulin paclitaxeltreated cells defects mitotic spindle assembly chromosome segregation cell division unlike tubulintargeting drugs colchicine inhibit microtubule assembly paclitaxel stabilizes microtubule polymer protects disassembly chromosomes thus unable achieve metaphase spindle configuration blocks progression mitosis prolonged activation mitotic checkpoint triggers apoptosis reversion cell cycle without cell ability paclitaxel inhibit spindle function generally attributed suppression microtubule studies demonstrated suppression dynamics occurs concentrations lower needed block mitosis higher therapeutic concentrations paclitaxel appears suppress microtubule detachment centrosomes process normally activated paclitaxel binds betatubulin subunits nomenclature paclitaxel structured tetracyclic skeleton total stereocenters active stereoisomer shown almost paclitaxel produced derived bark pacific yew taxus brevifolia harvesting kills tree processes used descendants original isolation method monroe wall mansukh wani us national cancer institute nci contracted hauser chemical research boulder colorado handle bark scale needed phase ii iii trialscitation needed size wild population pacific yew magnitude eventual demand paclitaxel uncertain clear alternative sustainable source natural product would needed initial attempts broaden sourcing used needles tree material related taxus species including cultivated onescitation needed attempts challenged relatively low often highly variable yields obtained early coincident increased sensitivity ecology forests pacific northwest paclitaxel successfully extracted clinically useful scale concurrently synthetic chemists us france interested paclitaxel beginning late needed noted extensive efforts underway accomplish total synthesis paclitaxel efforts motivated desire generate new chemical understanding rather achieve practical commercial production contrast french group pierre potier centre national de la recherche scientifique cnrs addressed matter overall process yield showing feasible isolate relatively large quantities compound european yew taxus baccata grew cnrs campus whose needles available large quantitycitation needed virtue structure seen viable starting material short semisynthesis produce paclitaxel poitier collaborators published semisynthetic route needles european yew view nci however even route practicalcitation needed group robert holton also pursued practical semisynthetic production route late holtons group developed semisynthetic route paclitaxel twice yield potier main innovation coupling ringopening method independently discovered holton florida state university holton worked signed deal bristolmyers squibb bms license semisynthesis future patentscitation needed holton patented improved process yield bms took process inhouse started manufacture paclitaxel ireland isolated needles european yewcitation needed early bms announced would cease reliance pacific yew bark end effectively terminating ecological controversy usecitation needed announcement also made good commitment develop alternative supply route made nci cooperative research development agreement crada application bms using semisynthetic method utilizing needles european yew produce another company worked bms phyton biotech inc uses plant cell fermentation pcf cultivating specific taxus cell line fermentation tanks longer need ongoing sourcing material actual yew tree paclitaxel captured directly suspension broth resin allowing concentration highly enriched powder containing paclitaxel compound purified one chromatographic step followed compared semisynthesis method pcf eliminates need many hazardous chemicals saves considerable amount paclitaxel discovered natural product newly described endophytic fungus living yew since reported number endophytic fungi including nodulisporium sylviformecitation needed alternaria taxi cladosporium cladosporioides metarhizium anisopliae aspergillus candidus mucor rouxianus chaetomella raphigera phyllosticta tabernaemontanae phomopsis pestalotiopsis pauciseta phyllosticta citricarpa podocarpus sp fusarium solani pestalotiopsis terminaliae pestalotiopsis breviseta botryodiplodia theobromae gliocladium sp alternaria alternata var monosporus cladosporium cladosporioides nigrospora sp pestalotiopsis versicolor taxomyces andreanae however contradictory evidence production endophytes studies finding independent production taxol tetracyclic diterpene biosynthesis diterpenes starts fpp molecule elongated addition ipp molecule order form geranylgeranyl diphosphate biosynthesis taxol contains nineteen steps considered several steps first step formation taxane skeleton undergoes series oxygenations following oxygenations two acetylations benzoylation occur intermediate oxygenation taxane core believed occur followed hydroxylation later pathway later pathway oxidation forms ketone functional group oxetane forming intermediate baccatin iii final steps pathway include formation chain attached baccatin biosynthesis taxol illustrated detail figure steps occurring enzyme taxadiene synthase ts figure taxols biosynthesis begins eeeggpp losing pyrophosphate via mechanism step figure doublebond attacks cation via electrophilic addition yielding tertiary cation creating first ring closure step another electrophilic attack occurs cyclizing structure creating first ring creating another tertiary cation step intramolecular proton transfer occurs attacking verticillyl cation step creating double bond yielding tertiary cation electrophilic cyclization occurs step intramolecular proton transfer attacks taxenyl cation step forms fused ring structure intermediate known taxadiene taxadiene undergoes series oxidations via nadph forming intermediate multiple steps later figure series hydroxylations esterficiations occur forming intermediate iii undergoes series esterifications sidechain finally yields product taxol least thirty academic research teams globally working achieve total synthesis natural product synthesis proceeding simple natural products readily available starting total synthesis effort motivated primarily desire generate new chemical understanding rather expectation practical commercial production paclitaxel first laboratories complete total synthesis much less complex starting materials research groups robert holton first article accepted publication k c nicolaou first article appear print week february though holton submission preceded nicolaou month december versus january near coincidence publications arising massive multiyear authors appearing february led ending race termed photo though group argued synthetic strategy tactics five additional research groups reported successful total syntheses paclitaxel wender et al kuwajima et al mukaiyama et al linear syntheses danishefsky et al takahashi et al convergent synthesesneeds update date strategies aimed prepare core containing abcd ring system followed generally last stage addition tail political climate surrounding paclitaxel pacific yew early helped bolster link total synthesis paclitaxel supply problem though total synthesis activities requisite explore structureactivity relationships paclitaxel via generation analogs testing total synthesis efforts never seen serious commercial route provide significant quantities natural product medical testing therapeutic discovery paclitaxel began result ncifunded screening number years later isolated bark pacific yew taxus brevifolia hence name discovery made monroe e wall mansukh c wani research triangle institute research triangle park north carolina scientists isolated natural product bark pacific yew tree determined structure named taxol arranged first biological testingcitation needed compound developed commercially bms generic name assigned paclitaxelcitation needed nci united states set cancer chemotherapy national service center ccnsc act public screening center anticancer activity compounds submitted external institutions although majority compounds screened synthetic origin one chemist jonathan hartwell employed onwards experience natural product derived compounds began plant screening years informal arrangements july nci commissioned united states department agriculture usda botanists collect samples plant species per august one botanists arthur barclay collected bark single pacific yew tree forest north town packwood washington part fourmonth trip collect material different species material processed number specialist ccnsc subcontractors one trees samples found cytotoxic cellular assay may accordingly late early fractionation isolation laboratory run monroe e wall research triangle park north carolina began work fresh taxus samples isolating active ingredient september announcing findings april american chemical society meeting miami named pure compound taxol june wall colleague wani published results including chemical structure nci continued commission work collect taxus bark isolate increasing quantities taxol kg lb crude extract isolated almost kg lb bark although ultimately yielded g oz pure several years use made compound nci shown active another vitro system two years later new department head reviewed data finally recommended taxol moved next stage discovery required increasing quantities purified taxol g oz request lb kg bark made two nci researchers published report showing taxol mildly effective leukaemic november taxol shown effective xenograft meanwhile taxol began well known cell biology well cancer community publication early susan b horwitz molecular pharmacologist albert einstein college medicine showing taxol previously unknown mechanism action involving stabilization microtubules together formulation problems increased interest researchers meant nci envisaged needing collect lb kg animal toxicology studies complete june november nci applied ind necessary begin clinical trials phase clinical trials began april decision start phase ii trials made year larger trials needed bark collection pounds commissioned enabled phase ii trials begin end recognized demand taxol might substantial pounds bark might needed minimum unprecedentedly large amount brought ecological concerns impact yew populations focus first time local politicians foresters expressed unease first public report phase ii trial may showed promising effects melanoma refractory ovarian point gordon cragg ncis natural product branch calculated synthesis enough taxol treat ovarian cancer melanoma cases us would require destruction trees annually first time serious consideration given problem practical particular financial scale program needed nci decided seek association pharmaceutical company august published cooperative research development agreement crada offering current stock supply current bark stocks proprietary access data far collected company willing commit providing funds collect raw material isolate taxol fund large proportion clinical trials words goodman welsh authors substantial scholarly book taxol nci thinking collaboration handover taxol although offer widely advertised four companies responded crada including american firm bristolmyers squibb bms selected partner december choice bms later became controversial subject congressional hearings seems clear nci little choice seek commercial partner also controversy terms deal eventually leading report general accounting office concluded nih failed ensure value related cradas usda department interior bristolmyers squibb given exclusive first refusal federal supplies taxus brevifolia exclusive contract lead criticism giving bms cancer eighteen months crada bms filed new drug application nda given fda approval end although patent compound provisions waxmanhatch act gave bristolmyers squibb five years exclusive marketing rights bms applied trademark name taxol taxolr controversially approved time paclitaxel replaced taxol generic inn name compound critics including journal nature argued name taxol used two decades scientific articles suggested trademark awarded bms renounce rights bms argued changing name would cause confusion among oncologists possibly endanger health patients bms continued defend rights name bms also criticized misrepresentation goodman walsh quote company report saying testing enabled isolation paclitaxel initially described compound quote strictly speaking accurate objection seems misleadingly neglects explain scientist isolation named compound taxol referred way twenty years annual sales peaked reaching billion paclitaxel available generic form cost nhs per patient early breast cancer assuming four cycles treatment approx caffeine speculated inhibit paclitaxelinduced apoptosis colorectal cancer aside direct clinical use paclitaxel used extensively biological biomedical research microtubule stabilizer general vitro assays involving microtubules motility assays rely paclitaxel maintain microtubule integrity absence various nucleating factors stabilizing elements found cell example used vitro tests drugs aim alter behavior microtubule motor proteins studies mutant motor proteins moreover paclitaxel used vitro inhibit insulin fibrillation molar ratio insulinpaclitaxel hindered insulin fibrillation near isothermal titration calorimetry itc findings indicated spontaneous tendency paclitaxel interact insulin hydrogen bonds van der waals also inhibitory role paclitaxel attributed impact colloidal stability protein solution observed paclitaxel inhibited lysozyme fibrillation inducing formation offpathway oligomeric intermediates increasing colloidal stability paclitaxel sometimes used vivo studies well fed test organisms fruit flies injected individual cells inhibit microtubule disassembly increase number microtubules cell paclitaxel induces remyelination demyelinating mouse inhibits vitro though methyl ester side angiotech pharmaceuticals inc began phase ii clinical trials multiple sclerosis treatment reported results showed statistical vitro multidrug resistant mouse tumor cells treated paclitaxel encased exosomes doses less common dosing effect also dyemarked exosomes able mark tumor cells potentially aiding spacefilling model paclitaxel rotating paclitaxel molecule model crystal structure paclitaxel total charge surface taxol minimum energy conformation httpsenwikipediaorgwikipaclitaxel